UY39097A - Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético - Google Patents

Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético

Info

Publication number
UY39097A
UY39097A UY0001039097A UY39097A UY39097A UY 39097 A UY39097 A UY 39097A UY 0001039097 A UY0001039097 A UY 0001039097A UY 39097 A UY39097 A UY 39097A UY 39097 A UY39097 A UY 39097A
Authority
UY
Uruguay
Prior art keywords
quinazolin
piperazin
fluoro
potassium salt
acid
Prior art date
Application number
UY0001039097A
Other languages
English (en)
Inventor
Helmut Buschmann
Thomas Goldner
Carles Ceron Bertran Jordi
Original Assignee
Aic246 Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Gmbh & Co Kg filed Critical Aic246 Gmbh & Co Kg
Publication of UY39097A publication Critical patent/UY39097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a la sal de potasio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético y solvatos de la misma. La invención se refiere además a métodos de preparación de dicha sal de potasio del ácido 2-[(4S)-8-fluoro 2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético o solvatos de la misma, así como composiciones farmacéuticas que comprenden dicha sal.
UY0001039097A 2020-02-27 2021-02-26 Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético UY39097A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159742 2020-02-27

Publications (1)

Publication Number Publication Date
UY39097A true UY39097A (es) 2021-09-30

Family

ID=69742731

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039097A UY39097A (es) 2020-02-27 2021-02-26 Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético

Country Status (19)

Country Link
US (1) US20230150950A1 (es)
EP (1) EP4110471A1 (es)
JP (1) JP7512405B2 (es)
KR (1) KR20220148860A (es)
CN (1) CN115427112B (es)
AR (1) AR121437A1 (es)
AU (1) AU2021227281B2 (es)
BR (1) BR112022016890A2 (es)
CA (1) CA3169075A1 (es)
CL (1) CL2022002294A1 (es)
CO (1) CO2022012006A2 (es)
CU (1) CU20220046A7 (es)
EC (1) ECSP22066666A (es)
IL (1) IL295644A (es)
MX (1) MX2022010442A (es)
PE (1) PE20230512A1 (es)
TW (1) TWI819279B (es)
UY (1) UY39097A (es)
WO (1) WO2021170882A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
PE20230512A1 (es) 2023-03-24
CN115427112A (zh) 2022-12-02
ECSP22066666A (es) 2022-12-30
MX2022010442A (es) 2022-10-18
CU20220046A7 (es) 2023-04-10
WO2021170882A1 (en) 2021-09-02
EP4110471A1 (en) 2023-01-04
JP7512405B2 (ja) 2024-07-08
CL2022002294A1 (es) 2023-02-03
JP2023524349A (ja) 2023-06-12
IL295644A (en) 2022-10-01
CN115427112B (zh) 2024-10-11
AR121437A1 (es) 2022-06-08
KR20220148860A (ko) 2022-11-07
TW202140455A (zh) 2021-11-01
US20230150950A1 (en) 2023-05-18
TWI819279B (zh) 2023-10-21
AU2021227281B2 (en) 2024-07-18
BR112022016890A2 (pt) 2022-12-06
CA3169075A1 (en) 2021-09-02
AU2021227281A1 (en) 2022-10-13
CO2022012006A2 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
CY1117796T1 (el) Μετα νατριου και ασβεστιου αλατα παραγωγου διυδροκινζολινης και η χρηση αυτων ως αντι-ιικα μεσα
EA201892450A1 (ru) Ароматические сульфонамидные производные
ECSP10010223A (es) Derivados de aminobenzamida como agentes útiles para el control de parásitos de animales
PE20160863A1 (es) Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
DOP2010000165A (es) 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso como inhibidores de la elastasa neutrofila humana
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
RS54205B1 (en) L-PROLINE AND CO-CRYSTALS OF LUMIC ACID OF (2S, 3R, 4R, 5S, 6R) -2- (3 ((5- (4-FLUOROPHENYL) THIOPHEN-2-IL) METHYL-4-METHYLPHENYL) -6- (HYDROXYMETHYL) TETRAHYDRO-2H-PYRAN-3, 4, 5-TRIOLA
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
CL2024000757A1 (es) Sal de 1,2-etanodisulfonato de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
NZ628444A (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
NZ589504A (en) Substituted carbinol compound having cyclic linker
BR112018014133A2 (pt) derivados de heterocicleno como agentes de controle de praga
PE20211757A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
UY39097A (es) Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
EA201270653A1 (ru) Антагонист dpи его применение
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana